**KIES PETER** Form 4 July 11, 2018

## FORM 4

#### **OMB APPROVAL**

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

**OMB** 3235-0287 Number:

Check this box if no longer subject to Section 16. Form 4 or

January 31, Expires: 2005

Form 5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES** 

Estimated average burden hours per response... 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940 See Instruction

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* 5. Relationship of Reporting Person(s) to 2. Issuer Name and Ticker or Trading **KIES PETER** Issuer Symbol INOVIO PHARMACEUTICALS, (Check all applicable) INC. [INO] (Last) (First) (Middle) 3. Date of Earliest Transaction Director 10% Owner X\_ Officer (give title \_ Other (specify (Month/Day/Year)

C/O INOVIO PHARMACEUTICALS, INC., 6769

MESA RIDGE ROAD

(Street) 4. If Amendment, Date Original

07/09/2018

Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

below)

**CFO** 

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

Person

below)

SAN DIEGO, CA 92121

(City)	(State) (	Zip) Table	e I - Non-D	erivative S	ecuri	ties Acq	uired, Disposed o	of, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	, , ,			Securities Form: Direct Beneficially (D) or Owned Indirect (I) Following (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code V	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		
Common Stock	07/09/2018		M	15,000	A	\$ 4.24	97,088	D	
Common Stock	07/09/2018		S	25,000	D	\$ 4.43 (1)	72,088	D	
Common Stock	07/10/2018		S	10,000	D	\$ 4.45 (2)	62,088	D	
Common							4,500	I	By Spouse

#### Stock

Stock

Option

k

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

15,000

07/09/2008(4) 07/09/2018

(9-02)

Common

Stock

15,00

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

<ol> <li>Title of</li> </ol>	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	<ol><li>Date Exercisable</li></ol>	and	7. Title and A	Amount
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	TransactionDerivative		Expiration Date		Underlying Securities	
Security	or Exercise		any	Code	Securities	(Month/Day/Year)		(Instr. 3 and 4)	
(Instr. 3)	Price of		(Month/Day/Year)	(Instr. 8)	Acquired (A)				
	Derivative				or Disposed of				
	Security				(D)				
					(Instr. 3, 4,				
					and 5)				
						Date Exercisable	Expiration Date	Title	Amour or Numbe
				Code V	(A) (D)				of Shar
Common					15.000				1.7.00

M

### **Reporting Owners**

\$ 4.24 (3)

Reporting Owner Name / Address	Relationships				
1	Director	10% Owner	Officer	Other	
KIES PETER					
C/O INOVIO PHARMACEUTICALS, INC.			CFO		
6769 MESA RIDGE ROAD					

## **Signatures**

SAN DIEGO, CA 92121

Peter Kies 07/11/2018 \*\*Signature of Date Reporting Person

# **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

07/09/2018

- Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- This transaction was executed in multiple trades at prices ranging from \$4.42 to \$4.43, inclusive. The price reported in Column 4 is a (1) weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.
- (2) This transaction was executed in multiple trades at prices ranging from \$4.43 to \$4.46, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder

Reporting Owners 2

#### Edgar Filing: KIES PETER - Form 4

of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

- (3) Gives effect to a 1-for-4 reverse stock split effected by the Issuer on June 5, 2014.
- (4) The shares underlying this option vested and became exercisable on various dates between February 1, 2008 and February 1, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.